Traceability Archives - Helix Life Sciences AG

Counterfeit Ozempic: The EU’s EMVS Steps Up

Daniel Muscionico — Sat, 01 Jun 2024 15:05:59 +0000

Combating Counterfeit Ozempic: The EU’s EMVS Steps Up

In a recent development, the European Medicines Agency (EMA) has flagged the presence of counterfeit Ozempic pens in the EU market. These counterfeit pens, originating from wholesalers in Austria and Germany, bear the German language labelling and packaging and possess batch numbers, 2D barcodes, and unique serial numbers identical to those found on genuine Ozempic packs.

Fortunately, the EU Medicines Verification System (EMVS) has played a crucial role in detecting these counterfeit pens. EMVS, an EU-wide electronic system, assigns a unique identifier (UI) to each medicinal product, enabling real-time verification of product authenticity and traceability throughout the distribution process. When the serial numbers of counterfeit Ozempic pens were scanned through EMVS, they were flagged as inactive, alerting authorities to a potential falsification.

The EMA has assured patients that there is no evidence of any counterfeit pens being dispensed from legitimate pharmacies. However, they are collaborating with EU medicines regulatory authorities and the police to investigate the matter thoroughly. Wholesalers and pharmacies in the affected countries have been warned, and parallel distributors across the EU have also been informed.

The German and Austrian regulatory authorities have taken further action by issuing statements of non-compliance with good distribution practices (GDP) to the wholesalers involved. These wholesalers failed to adhere to required procedures, including compliance with security measures, thereby contributing to the counterfeiting of Ozempic.

The increased demand for Ozempic, sometimes used off-label for weight loss, has led to shortages, possibly creating an opportunity for counterfeiters to exploit. The emergence of counterfeit Ozempic highlights the importance of EMVS in protecting patients from the dangers of falsified medicines.

As we strive for a safer pharmaceutical supply chain, the EMVS stands as a valuable tool, enabling real-time verification and traceability, and safeguarding patients from the perils of counterfeit drugs.

The post Counterfeit Ozempic: The EU’s EMVS Steps Up appeared first on Helix Life Sciences AG.

IDMP: The Latest in Identification of Medicinal Products

Daniel Muscionico — Mon, 27 May 2024 20:28:49 +0000

As the pharmaceutical landscape continues to evolve, the need for standardized identification and management of medicinal products has never been more critical. The Identification of Medicinal Products (IDMP) standards, established by the International Organization for Standardization (ISO) and supported by regulatory bodies like the European Medicines Agency (EMA), are crucial for ensuring global consistency, safety, and efficiency in drug development and regulation. As of 2024, these standards are more relevant than ever for life sciences professionals.

What is IDMP?

IDMP encompasses a suite of five ISO standards (ISO 11615, ISO 11616, ISO 11238, ISO 11239, and ISO 11240) aimed at harmonizing the identification and exchange of medicinal product information. These standards are designed to facilitate the clear and consistent communication of product information across regulatory agencies and healthcare systems worldwide.

Key IDMP Standards

ISO 11615: Defines the identification of medicinal products, including both authorized and investigational drugs.
ISO 11616: Pertains to the identification of pharmaceutical products, specifying dose form and administration details.
ISO 11238: Relates to the identification of substances, including active ingredients and excipients.
ISO 11239: Addresses pharmaceutical dose forms, units of presentation, routes of administration, and packaging.
ISO 11240: Standardizes units of measurement used in medicinal product descriptions.

Benefits of IDMP Implementation

Regulatory Compliance and Global Harmonization

The EMA and other regulatory bodies have mandated the adoption of IDMP standards, making compliance essential for market access. These standards ensure that medicinal product data is consistent across different jurisdictions, streamlining regulatory submissions and approvals. For example, the EMA’s implementation of the SPOR (Substances, Products, Organizations, and Referentials) data management services is directly aligned with IDMP requirements.

Enhanced Pharmacovigilance and Patient Safety

IDMP standards improve pharmacovigilance by enabling more accurate tracking and reporting of adverse drug reactions. Standardized product information facilitates quicker identification of safety issues, supporting better risk management and enhancing patient safety.

Operational Efficiency and Data Integrity

Implementing IDMP can significantly improve operational efficiency within pharmaceutical companies. Standardized data formats reduce the risk of errors and discrepancies, leading to more reliable data management and interoperability between different systems and stakeholders.

Recent Developments and Challenges

EMA’s SPOR Initiative

The EMA’s SPOR initiative, which aligns with IDMP, has seen significant progress. The SPOR platform enables the efficient management of substance, product, organization, and referential data, providing a robust foundation for IDMP compliance. The ongoing updates to SPOR services, including enhanced data validation and integration capabilities, are crucial for maintaining compliance and operational efficiency in 2024.

Implementation Challenges

Despite the clear benefits, implementing IDMP is not without challenges. Data harmonization across legacy systems, integrating new IT solutions, and ensuring staff are trained on new processes require significant resources and strategic planning. Companies must develop comprehensive implementation plans, often requiring expert guidance to navigate these complexities effectively.

How Helix Life Sciences Can Support Your IDMP Journey

At Helix Life Sciences, we understand the intricacies of IDMP implementation and the challenges it presents. Our team of experts offers tailored consulting services to help pharmaceutical companies achieve compliance with the latest IDMP standards. We provide strategic support, from data harmonization and system integration to staff training and regulatory submission preparation.

For more information on how we can assist with your IDMP needs, visit our website or contact us directly. Helix Life Sciences is committed to helping you navigate the complexities of IDMP, ensuring your products meet the highest standards of regulatory compliance and patient safety.

The post IDMP: The Latest in Identification of Medicinal Products appeared first on Helix Life Sciences AG.

EMVS: Challenges and Opportunities for Pharmaceutical Industry Stakeholders

wpadmin — Mon, 12 Feb 2024 08:22:06 +0000

Navigating the Evolving Landscape of EMVS: Challenges and Opportunities for Pharmaceutical Industry Stakeholders

The European Medicines Verification System (EMVS) has been a game-changer in enhancing the safety and integrity of the pharmaceutical supply chain across Europe. By implementing a unique identifier (UI) for each medicinal product, EMVS facilitates the real-time verification of product authenticity and traceability throughout the distribution process.

While EMVS has undoubtedly improved the security of the pharmaceutical supply chain, it also presents a set of challenges that pharmaceutical industry stakeholders must address to ensure seamless implementation and long-term success.

Data Harmonization and Integration

One of the primary challenges lies in harmonizing and integrating data across the EMVS ecosystem. Manufacturers, distributors, and pharmacies must ensure that product data, including UIs and related information, is accurately and consistently captured, transmitted, and stored in their respective systems. This requires robust data management practices and interoperability between different software applications.

Cybersecurity Risks

As EMVS relies on digital data and connectivity, cybersecurity risks become a pressing concern. Protecting sensitive product information from unauthorized access, modification, or disruption is crucial to maintaining the integrity of the verification process. Pharmaceutical companies must implement robust cybersecurity measures, including encryption, access controls, and regular vulnerability assessments, to safeguard their systems.

Compliance and Training

Maintaining compliance with EMVS regulations is essential for all stakeholders. Manufacturers must ensure that product UIs are properly assigned and recorded, while distributors and pharmacies must effectively verify the authenticity of products before dispensing them. Comprehensive training programs are crucial to equip personnel with the necessary knowledge and skills to comply with EMVS requirements.

Switzerland’s EMVS Adoption

Switzerland, while not a member of the European Union, has voluntarily adopted EMVS to enhance the security of its pharmaceutical supply chain. This integration has presented unique challenges and opportunities for Swiss stakeholders.

Challenges:

Data Interoperability:Switzerland’s EMVS system, known as the Swiss National Medicine Verification System (NMVS), needs to interoperate seamlessly with the EU’s EMVS to facilitate cross-border verification.
Technical Compatibility:Swiss pharmaceutical companies and pharmacies must ensure that their systems are compatible with the EU’s EMVS standards to enable seamless data exchange.

Opportunities:

Enhanced Supply Chain Security:Adoption of EMVS aligns Switzerland’s pharmaceutical supply chain with the high standards set by the EU, promoting overall security and reducing the risk of counterfeit medicines entering the market.
International Collaboration:Switzerland’s voluntary adoption of EMVS fosters closer collaboration with EU counterparts in addressing supply chain security challenges and harmonizing standards.

Conclusion

As the pharmaceutical industry continues to evolve, EMVS will play an increasingly important role in ensuring the safety and integrity of medicines across Europe and beyond. Pharmaceutical manufacturers, distributors, and pharmacies must proactively address the challenges posed by EMVS to derive its full benefits and maintain a secure supply chain. Collaboration, data harmonization, and robust cybersecurity measures will be key to navigating the evolving landscape of EMVS and ensuring its ongoing success.

The post EMVS: Challenges and Opportunities for Pharmaceutical Industry Stakeholders appeared first on Helix Life Sciences AG.